Palatin Technologies, Inc. (PTN)

Market Cap	18.92M
Revenue (ttm)	2.38M
Net Income (ttm)	-32.35M
Shares Out	19.55M
EPS (ttm)	-1.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,953,763
Open	0.930
Previous Close	0.860
Day's Range	0.917 - 1.200
52-Week Range	0.680 - 5.650
Beta	0.91
Analysts	Strong Buy
Price Target	17.00 (+1,656.38%)
Earnings Date	Feb 13, 2025

About PTN

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 28, 1993
• Employees: 30
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PTN
• Website: https://palatin.com

Financial Performance

In 2024, Palatin Technologies's revenue was $4.49 million, a decrease of -7.49% compared to the previous year's $4.85 million. Losses were -$29.74 million, 23.7% more than in 2023.

Analyst Forecast

According to one analyst, the rating for PTN stock is "Strong Buy" and the 12-month stock price forecast is $17.0.

Price Target

$17.0

(1,656.38% upside)

Analyst Consensus: Strong Buy